2007
DOI: 10.7124/bc.00075a
|View full text |Cite
|
Sign up to set email alerts
|

The development of DNA-vaccine against classical swine fever

Abstract: The development of a DNA-vaccine against classical swine fever (CSF) is a perspective direction, because it gives an opportunity to develop a marker vaccine due to use of a part of protective antigen molecule, and to induce effectively both cellular and humoral immune response. In this study a recombinant plasmid, containing the fragment of E2 gene of CFS virus (CSFV) in eukaryotic expression vector, has been developed. It has been demonstrated that the fragment of E2 protein of CSFV is expressed in CHO-K1 cel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
5
0
4

Year Published

2012
2012
2021
2021

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(10 citation statements)
references
References 17 publications
1
5
0
4
Order By: Relevance
“…The advantages of DNA vaccines include their ability to induce both humoral and cellular immune responses, relatively low cost of manufacturing, temperature stability, and the possibility of rapid modification of the initial constructs [3]. Previously, we described the candidate marker DNA-vaccine against CSF based on the fragment of a gene of E2 glycoprotein of CSFV, in eukaryotic expression cassette, placed between inverted terminal repeats (ITRs) from human adeno-associated virus-2 (AAV-2) [4]. We also demonstrated that the immunization of mice with constructed recombinant vector elicited humoral immune response to chimeric E2 protein.…”
Section: Introductionmentioning
confidence: 99%
“…The advantages of DNA vaccines include their ability to induce both humoral and cellular immune responses, relatively low cost of manufacturing, temperature stability, and the possibility of rapid modification of the initial constructs [3]. Previously, we described the candidate marker DNA-vaccine against CSF based on the fragment of a gene of E2 glycoprotein of CSFV, in eukaryotic expression cassette, placed between inverted terminal repeats (ITRs) from human adeno-associated virus-2 (AAV-2) [4]. We also demonstrated that the immunization of mice with constructed recombinant vector elicited humoral immune response to chimeric E2 protein.…”
Section: Introductionmentioning
confidence: 99%
“…Для посилення імунної відповіді на експериментальну марковану ДНК-вакцину проти класичної чуми свиней (КЧС) -інфекційного захворювання, внесеного до переліку особливо небезпечних захворювань Міжнародного епізоотичного бюро, -про створення якої повідомлялося раніше [3], ми використали гени двох цитокінів -інтерлейкіну-2 та інтерлейкіну-12. Інтерлейкін-2 (ІЛ-2), який продукується активованими CD4 + Т-клітинами, є одним із ключових факторів, які впливають на ріст та активацію цитотоксичних Т-лімфоцитів, В-лімфоцитів макрофагів та клітин природних кілерів [4,5].…”
unclassified
“…Матеріали і методи У роботі були використані такі плазміди: pTR-BKneoта pBG-TR/01 (створені нами раніше [3,15]), pTR-UFneo-(створена Топоровою О. К. (неопубліковані дані)); pGT60mIL2 та pGT60mIL12 (Invivogene, США), pEGFP-N2, pEGFP-C1 (ClonTech, США), pET24-EGFP.…”
unclassified
See 2 more Smart Citations